R
RTW Investments, LP
+ Con en carteraZLAB
-10.67%
Rentabilidad a 3 meses
$24.060
+0.902 (+3.75%)Al cierre
Loading chart…
- Máximo
- 24.375
- Apertura
- 23.950
- Precio medio ponderado por volumen
- 24.05
- Volumen
- 383.63K
- Capitalización
- 1.73B
- Mínimo
- 23.700
- Importe
- 9.22M
- EV/EBITDA, TTM
- -5.90
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Análisis de IA of Zai Lab Ltd (ZLAB)
MantenerZai Lab Ltd is currently a hold. The stock is priced at $23.19, which is below analysts' targets of $36 and $45, indicating potential upside. However, the RSI is at 35.544, suggesting the stock is nearing oversold territory, yet it has recently declined by 7.20% over the last five days, indicating short-term weakness. The company continues to report negative earnings, with a net income of -51,016,000 USD in Q1 2026 and -50,825,000 USD in Q2 2026, which raises concerns about its profitability. The main risk is the significant insider selling activity, which has increased by 126% over the last month, potentially signaling lack of confidence among insiders.
Recomendaciones de analistas (3)
+99.21% de potencial alcista
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 24.06
Mínimo
25.70
Promedio
47.93
Máximo
74.00
JPMorgan
Sobreponderar
$36
2026-08-27
JPMorgan
2026-08-27
Precio objetivo
$36
Sobreponderar
Citi
Comprar
$45
2026-08-07
Citi
2026-08-07
Precio objetivo
$45
Comprar
Citi
Comprar
$44
2026-05-08
Citi
2026-05-08
Precio objetivo
$44
Comprar
JPMorgan
Sobreponderar
$32
2026-03-18
JPMorgan
2026-03-18
Precio objetivo
$32
Sobreponderar
Cantor Fitzgerald
Sobreponderar
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
Precio objetivo
$37
Sobreponderar
Métricas de valoración
El PER previsto actual de Zai Lab Ltd (ZLAB) es 0.00, frente a su media de 5 años de -16.18.
Ballenas con ZLAB en cartera
Cronología de eventos
Noticias
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
Preguntas frecuentes sobre ZLAB, respondidas por Alphio AI
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently a hold. The stock is priced at $23.19, which is below analysts' targets of $36 and $45, indicating potential upside. However, the RSI is at 35.544, suggesting the stock is nearing oversold territory, yet it has recently declined by 7.20% over the last five days, indicating short-term weakness. The company continues to report negative earnings, with a net income of -51,016,000 USD in Q1 2026 and -50,825,000 USD in Q2 2026, which raises concerns about its profitability. The main risk is the significant insider selling activity, which has increased by 126% over the last month, potentially signaling lack of confidence among insiders.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.